ES2337435B8 - Compuestos potenciadores de la actividad de glicosidasas mutantes. - Google Patents

Compuestos potenciadores de la actividad de glicosidasas mutantes. Download PDF

Info

Publication number
ES2337435B8
ES2337435B8 ES200802988A ES200802988A ES2337435B8 ES 2337435 B8 ES2337435 B8 ES 2337435B8 ES 200802988 A ES200802988 A ES 200802988A ES 200802988 A ES200802988 A ES 200802988A ES 2337435 B8 ES2337435 B8 ES 2337435B8
Authority
ES
Spain
Prior art keywords
activity
mutant
glycosidases
compounds
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200802988A
Other languages
English (en)
Other versions
ES2337435A1 (es
ES2337435B2 (es
Inventor
Ma. Isabel Garcia Moreno
Kousaku Ohno
Jose Manuel Garcia Fernandez
Yoshiyuki Suzuki
Carmen Ortiz Mellet
Matilde Aguilar Moncayo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INTERNAT UNIVERSITY OF HEALTH AND WELFARE
INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE (25%)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Sevilla
Tottori University NUC
Original Assignee
INTERNAT UNIVERSITY OF HEALTH AND WELFARE
INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE (25%)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Sevilla
Tottori University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INTERNAT UNIVERSITY OF HEALTH AND WELFARE, INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE (25%), Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Sevilla, Tottori University NUC filed Critical INTERNAT UNIVERSITY OF HEALTH AND WELFARE
Priority to ES200802988A priority Critical patent/ES2337435B8/es
Priority to PCT/ES2009/070449 priority patent/WO2010046517A1/es
Publication of ES2337435A1 publication Critical patent/ES2337435A1/es
Application granted granted Critical
Publication of ES2337435B2 publication Critical patent/ES2337435B2/es
Publication of ES2337435B8 publication Critical patent/ES2337435B8/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compuestos potenciadores de la actividad de glicosidasas mutantes, con actividad inhibidoras de enzimas glicosidasas y también se refiere a un procedimiento para la activación de \beta-glucosidasa mutante (\beta-glucocerebrosidasa) y \beta-galactosidasa mutante en pacientes que padecen trastornos de almacenamiento lisosómico mediante la administración de dichos compuestos inhibidores competitivos de las enzimas, caracterizados por una especificidad de unión muy alta y una relación favorable entre su concentración para actividad de chaperona farmacológica y su concentración para actividad inhibidora.
ES200802988A 2008-10-22 2008-10-22 Compuestos potenciadores de la actividad de glicosidasas mutantes. Expired - Fee Related ES2337435B8 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES200802988A ES2337435B8 (es) 2008-10-22 2008-10-22 Compuestos potenciadores de la actividad de glicosidasas mutantes.
PCT/ES2009/070449 WO2010046517A1 (es) 2008-10-22 2009-10-21 Compuestos potenciadores de la actividad de glicosidasas mutantes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200802988A ES2337435B8 (es) 2008-10-22 2008-10-22 Compuestos potenciadores de la actividad de glicosidasas mutantes.

Publications (3)

Publication Number Publication Date
ES2337435A1 ES2337435A1 (es) 2010-04-23
ES2337435B2 ES2337435B2 (es) 2011-01-25
ES2337435B8 true ES2337435B8 (es) 2011-07-19

Family

ID=42082773

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200802988A Expired - Fee Related ES2337435B8 (es) 2008-10-22 2008-10-22 Compuestos potenciadores de la actividad de glicosidasas mutantes.

Country Status (2)

Country Link
ES (1) ES2337435B8 (es)
WO (1) WO2010046517A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370852B1 (es) * 2010-06-04 2012-10-30 Consejo Superior De Investigaciones Científicas (Csic) Derivados sp2, imnoazúcar como inhibidores de las alfa-glicosidasas.
WO2016120808A1 (en) 2015-01-28 2016-08-04 Minoryx Therapeutics S.L. Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof
BR112019013593A2 (pt) 2016-12-28 2020-01-07 Minoryx Therapeutics S.L. Compostos de isoquinolina, métodos para sua preparação, e usos terapêuticos dos mesmos em afecções associadas à alteração da atividade de beta galactosidase
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
CN111006928B (zh) * 2019-12-26 2023-08-08 武汉三鹰生物技术有限公司 一种应用于免疫组织化学的封闭液及其使用方法
US20230391796A1 (en) * 2020-09-25 2023-12-07 Universidad De Sevilla (Us) -University Of Seville (Us) Glycosidase inhibitors and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3722827A1 (de) * 1987-07-07 1989-01-19 Schering Ag Anellierte imino-azole und imino-azine, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung
DE4002366A1 (de) * 1990-01-25 1991-08-01 Schering Ag Verfahren und zwischenprodukte zur herstellung von anellierten iminothiazolen

Also Published As

Publication number Publication date
ES2337435A1 (es) 2010-04-23
ES2337435B2 (es) 2011-01-25
WO2010046517A1 (es) 2010-04-29

Similar Documents

Publication Publication Date Title
ES2337435B8 (es) Compuestos potenciadores de la actividad de glicosidasas mutantes.
Toth et al. Resveratrol treatment rescues neurovascular coupling in aged mice: role of improved cerebromicrovascular endothelial function and downregulation of NADPH oxidase
JP2009137973A5 (es)
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
NL300874I2 (nl) Elosulfase alfa
ME01239B (me) Čvrsti preparat koji sadrži alogliptin i pioglitazon
WO2008109677A3 (en) Modified enzyme and treatment method
WO2006029319A3 (en) Modulating phosphatase activity in cardiac cells
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
BR112012018386A2 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
WO2011163648A8 (en) Cns delivery of therapeutic agents
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
WO2011050206A3 (en) Compositions and methods for the treatment of sinonasal disorders
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
NZ595196A (en) Peptide-based compounds for enzyme inhibition
UY31265A (es) (2s,3 r)-n-( 2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
ES2532985T3 (es) Proteínas quiméricas de toxoide de Shiga
PE20011350A1 (es) PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2010127152A3 (en) Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
MX2010003259A (es) Ensayo de monitoreo de farmacos.
WO2008137816A8 (en) Tricyclic compounds as matrix metalloproteinase inhibitors
WO2009023773A3 (en) Galactokinase inhibitors
WO2008106166A3 (en) Methods for the treatment of liver diseases using specified matrix metalloproteinase (mmp) inhibitors

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20100423

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2337435

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20110113

FD2A Announcement of lapse in spain

Effective date: 20180924